T2DM: DAPAGLIFLOZIN, METFORMIN XR, OR BOTH
In treatment-naïve patients with type 2 diabetes (T2D), initial combination therapy with dapagliflozin + extended-release metformin (MET XR) resulted in significant improvements in glycaemic and weight outcomes. Dapagliflozin + MET XR provided superior glycaemic benefits to monotherapy with either agent. The combination treatment was generally well tolerated.
James F. List
Princeton, New Jersey, Us